Fernando Larcher
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Sephardic origins revealed for rare skin disorder, recessive dystrophic epidermolysis bullosa, in individuals carrying the unique c.6527insC mutation.
Journal: Journal of medical genetics
Published: June 01, 2025
Safe and Efficacious Permanent Removal of Large COL7A1 Exons for Gene Reframing as a Reliable Therapeutic Strategy for Recessive Dystrophic Epidermolysis Bullosa.
Journal: Human gene therapy
Published: May 28, 2025
The Importance of Shared Patient Voices in Advancing Science for Genodermatoses on a Global Scale.
Journal: The Journal of investigative dermatology
Published: May 14, 2025
Base edited skin equivalents with clinical potential for ex vivo correction of recessive dystrophic epidermolysis bullosa.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: March 04, 2025
Targeting olfactory receptor OR2AT4: An innovative aptamer-based treatment for hair growth promotion.
Journal: Molecular therapy. Nucleic acids
Published: December 23, 2024
Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa.
Journal: Scientific reports
Published: March 04, 2024
Evaluation of Systemic Gentamicin as Translational Readthrough Therapy for a Patient With Epidermolysis Bullosa Simplex With Muscular Dystrophy Owing to PLEC1 Pathogenic Nonsense Variants.
Journal: JAMA dermatology
Published: March 02, 2022
Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectors.
Journal: Molecular therapy. Methods & clinical development
Published: January 13, 2022
Paired nicking-mediated COL17A1 reframing for junctional epidermolysis bullosa.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: November 09, 2021
Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-β antagonist and inhibitor of fibrosis.
Journal: Matrix biology : journal of the International Society for Matrix Biology
Published: September 30, 2021
Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 08, 2020
Last Updated: 09/26/2026